Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

• Healthy males aged 20 - 40 and healthy males aged greater than 65.

• Body mass index range of 17.6 - 26.4 kg/m2 greater than or equal to 45 kg.

• Non-smokers or smoker of fewer than 10 cigarettes a day.